Advanced Human Imaging - General Discussion, page-247

It’s certainly a sell ATM, acquiring non revenue companies short term at the detriment of shareholder dilution.
Complicated company full stop. Every deal recently has cost the company money and or SH dilution should the deal bring revenue long term is the asking question?

At some stage all these deals that mostly are non binding, a Nasdaq listing forthcoming. Where is our revenue? With out a doubt the expense of above is going to impact and is clearly doing so by the recent news after coming out of halt.

Personally, Nasdaq well be under what ASX SP is, how they measure that and how many SOI is yet to be seen. Certainly bullish on the company however I think we lost our way a tad.

The spending on non revenue generating acquisitions is the issue for mine.

Please correct me, happy to open a genuine conversation and not attack.